KDR and breast cancer: In addition, a combined treatment with glipizide, a second‐generation sulfonylurea hypoglycemic agent, and ANP suppressed breast cancer growth and metastasis by the inhibition of angiogenesis via the VEGF/VEGFR2 signaling pathway [22].